CLINICAL TRIALS PROFILE FOR LOPINAVIR; RITONAVIR

505(b)(2) Clinical Trials for LOPINAVIR; RITONAVIR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.

All Clinical Trials for LOPINAVIR; RITONAVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004578 ↗	ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects	Completed	Abbott	Phase 1/Phase 2	1997-11-01	To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
NCT00006144 ↗	A Study of HIV-Disease Development in Aging	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2000-10-01	The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00014937 ↗	Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.
NCT00017992 ↗	Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV	Unknown status	Triangle Pharmaceuticals	Phase 2	1969-12-31	The purpose of this study is to see if emtricitabine is safe in children infected with HIV and to determine the best dose.
NCT00023218 ↗	Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty changes, scarring, abnormal liver function tests (LFTs), and lactic acidemia (an increase in lactic acid in the blood). Increased liver enzymes may mean liver damage. The way that the liver changes in people with abnormal LFTs and lactic acidemia is not completely understood.
NCT00025727 ↗	Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure	Unknown status	GlaxoSmithKline	Phase 3	2001-05-01	The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.

Clinical Trial Conditions for LOPINAVIR; RITONAVIR

Condition Name

Condition Name for LOPINAVIR; RITONAVIR
Intervention	Trials
HIV Infections	139
COVID-19	36
HIV	35
HIV Infection	32

Condition MeSH

Condition MeSH for LOPINAVIR; RITONAVIR
Intervention	Trials
HIV Infections	195
COVID-19	69
Acquired Immunodeficiency Syndrome	44
Infections	37

Clinical Trial Locations for LOPINAVIR; RITONAVIR

Trials by Country

Trials by Country for LOPINAVIR; RITONAVIR
Location	Trials
United States	770
Spain	88
Thailand	66
Canada	56
South Africa	54

Trials by US State

Trials by US State for LOPINAVIR; RITONAVIR
Location	Trials
California	62
New York	56
Florida	43
Texas	41
Illinois	40

Clinical Trial Progress for LOPINAVIR; RITONAVIR

Clinical Trial Phase

Clinical Trial Phase for LOPINAVIR; RITONAVIR
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	90
Phase 3	76

Clinical Trial Status

Clinical Trial Status for LOPINAVIR; RITONAVIR
Clinical Trial Phase	Trials
Completed	219
Recruiting	31
Terminated	30

Clinical Trial Sponsors for LOPINAVIR; RITONAVIR

Sponsor Name

Sponsor Name for LOPINAVIR; RITONAVIR
Sponsor	Trials
Abbott	55
National Institute of Allergy and Infectious Diseases (NIAID)	52
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	20

Sponsor Type

Sponsor Type for LOPINAVIR; RITONAVIR
Sponsor	Trials
Other	504
Industry	149
NIH	87

Clinical Trials Update, Market Analysis, and Projection: Lopinavir / Ritonavir

Last updated: April 27, 2026

Where does lopinavir/ritonavir stand in clinical development?

Lopinavir/ritonavir is an established antiretroviral (ARV) used in HIV treatment. Clinical development activity has been dominated by line extensions (formulation, population-specific studies, and comparative regimens) rather than new mechanism discoveries.

Key clinical-trial status (publicly trackable)

• HIV indication focus: ongoing interest is mainly in optimizing dosing, evaluating fixed-dose combinations, and assessing use in specific patient groups (e.g., pregnancy, co-infections, resistance contexts).
• COVID-19 signals were investigated clinically but are not reflected as a sustained, expanding global approval in the way they were initially expected, with practice generally shifting away from routine use as evidence matured. The pivotal early COVID-19 trials and subsequent evidence consolidation reduced uptake in many jurisdictions.

Regulatory placement

• The drug is long on the market and supported by an established safety and efficacy package. Clinical “update” activity is therefore better described as maintenance and optimization than discovery-stage expansion.

Clinical endpoints most commonly targeted in ongoing work

• Virologic suppression (HIV RNA decline to below thresholds)
• Resistance patterns under boosted protease inhibitor exposure
• Pharmacokinetics and tolerability in subpopulations (weight extremes, hepatic impairment, pregnancy)

What is driving or limiting lopinavir/ritonavir demand?

Demand is shaped by HIV regimen preferences, guideline positioning for boosted protease inhibitors, and competition from newer drug classes (integrase strand transfer inhibitors and next-generation ARVs).

Demand drivers

• Existing guideline footprint: boosted protease inhibitor regimens (including lopinavir/ritonavir) remain options in treatment histories, resistance scenarios, and when other drug classes are not suitable.
• Formulary familiarity and supply chain maturity: long market presence reduces adoption friction in high-volume settings.
• Use in treatment-experienced populations: protease inhibitors can retain utility where resistance patterns support continued effectiveness.

Demand constraints

• Class competition: INSTI-based regimens and long-acting strategies have shifted standard-of-care toward more convenient dosing and improved tolerability profiles.
• Tolerability burden: ritonavir boosting is associated with drug-drug interaction risk and gastrointestinal side effects in some patients, influencing regimen switching patterns.
• Reduced COVID-19 adoption: where lopinavir/ritonavir was used under emergency frameworks during earlier COVID-19 waves, sustained demand did not carry through broadly as evidence consolidated.

How big is the lopinavir/ritonavir market and where is it concentrated?

A robust, current-year revenue estimate requires payer, unit, and pricing data by country and channel. Without a complete dataset in this input, the only defensible market analysis is directional and anchored to known structural realities:

Market structure

• HIV is the core market. Any incremental COVID-19 usage is episodic and does not dominate long-run demand.
• Geographic concentration tends to be higher in regions with large ART programs and where older ARVs remain part of treatment continuity or procurement portfolios.
• Channel mix is typically characterized by government and donor-funded procurement in multiple high-burden settings, plus private payer use in higher-income markets where newer regimens lead.

Unit economics reality

• In mature ARVs with multiple generics, pricing pressure usually compresses revenue growth.
• Growth, where it occurs, tends to come from patient volume stability and program expansion, not premium pricing.

What is the near-term outlook for clinical and commercial trajectory?

Clinical outlook

• With a mature safety profile and established efficacy, trial activity is most likely to remain oriented around:
  • regimen positioning and comparative effectiveness studies
  • population-specific safety and PK optimization
  • formulation work to improve administration and adherence

Commercial outlook (12 to 36 months)

• Base case: steady to modest decline in developed markets due to regimen substitution toward newer classes and long-acting options.
• Emerging and high-burden markets: stability is more likely because ART continuity supports use of established regimens, with procurement decisions often favoring availability and cost.

What do market projections imply under realistic adoption dynamics?

A credible projection framework for mature HIV ARVs must separate: 1) Patient prevalence growth (drivers of total ART-treated population) 2) Regimen share drift (how treatment guidelines and physician prescribing shift among ARVs) 3) Pricing erosion (generic and tender price resets)

For lopinavir/ritonavir:

• Patient prevalence growth supports volume stability.
• Regimen share drift likely continues toward INSTI-based and other boosted or non-boosted alternatives.
• Pricing erosion persists in markets where generics compete.

Net implication: modest growth in units in some regions may be offset by declining revenue per unit globally, producing a generally flat-to-declining revenue trajectory in mature markets.

Competitive landscape: what replaces lopinavir/ritonavir?

The main competitive pressure is from:

• INSTI-based first-line and broadly used regimens that reduce reliance on ritonavir boosting
• fixed-dose combinations and improved tolerability profiles
• long-acting strategies that improve adherence for suitable patients

Lopinavir/ritonavir still has a role where protease inhibitors remain clinically indicated, but new patient starts increasingly target regimens perceived as simpler and better tolerated.

IP and lifecycle considerations that affect investment decisions

Lopinavir/ritonavir is widely available, and the market is functionally shaped by:

• patent and exclusivity status in specific jurisdictions
• generic entry and tender pricing
• fixed-dose and formulation IP where present (often fragmented by country and product format)

For business planning, the practical investment lens is:

• new clinical value must justify incremental adoption against entrenched generics and substitution dynamics
• value can concentrate in formulation improvements, combination strategy, and patient subgroups rather than brand-new mechanism differentiation

What should investors and R&D leaders watch next?

Clinical

• Updated comparative regimen outcomes in real-world cohorts
• PK and safety updates for special populations
• Evidence alignment with evolving guideline changes

Commercial

• Tender cycles and procurement pricing resets in high-volume regions
• Share changes driven by guideline updates and payer formulary management
• Supply stability in generic markets

Strategic options that remain rational for mature assets

• Optimization of formulations to reduce pill burden and improve adherence
• Targeted studies for patient groups with limited alternatives
• Line extensions that address real-world administration constraints

---

Key Takeaways

• Lopinavir/ritonavir is a mature HIV ARV with demand mainly tied to ongoing ART programs rather than new development breakthroughs.
• Clinical trial activity is likely to remain optimization- and positioning-focused, not mechanism-leading.
• Commercial growth is constrained by substitution toward INSTI-based regimens, tolerability and interaction burden from ritonavir boosting, and generic-driven pricing pressure.
• Market projections skew flat to modestly down on revenue, with regional variation driven by procurement dynamics and regimen share.

FAQs

1) Is lopinavir/ritonavir still used for HIV first-line therapy?
Often less frequently than earlier eras; it remains a regimen option where boosted protease inhibitor strategies fit clinical need and resistance or tolerability constraints.

2) Did COVID-19 evidence translate into sustained lopinavir/ritonavir demand?
Clinical use increased during early pandemic phases, but sustained broad adoption did not persist as evidence consolidated and practice shifted.

3) What drives regimen substitution away from lopinavir/ritonavir?
INSTI-based regimens and newer strategies that reduce reliance on ritonavir boosting and improve dosing convenience and tolerability.

4) Where can revenue be more stable despite generics?
Regions with large ART program continuity and procurement structures that prioritize supply availability and tender pricing, where patient switching can be slower.

5) What type of new studies are most credible for this asset?
Population-specific PK and safety work, comparative regimen outcomes, and formulation improvements that reduce administration burden.

---

References

[1] FDA. Drug Approval Packages: Kaletra (lopinavir and ritonavir). U.S. Food and Drug Administration.
[2] NIH (National Institutes of Health). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. U.S. Department of Health and Human Services.
[3] WHO. Guidelines for the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization.
[4] ClinicalTrials.gov. Lopinavir; Ritonavir (search results and study records). U.S. National Library of Medicine.